Eco Animal Health Group PLC
11 September 2026
11 September 2026
ECO Animal Health Group plc
(“ECO” or the “Company”)
Share Awards to Executive Directors
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developingandmarketing branded veterinary products to improve livestock productivity and welfare, announces that on 9 September 2026, nominal cost conditional share options were granted under the Company’s Long Term Incentive Plan (“LTIP”) over 404,526 ordinary shares in the Company (representing approximately 0.60 percent of the Company’s issued share capital) to the Executive Directors listed below.
|
Name |
Position |
Number of Share Awards |
|
David Hallas |
Chief Executive Officer |
232,449 |
|
Chris Wilks |
Chief Financial Officer |
172,077 |
These awards under the LTIP are subject to performance conditions being met which have been set by the Company’s Remuneration Committee and relate to Total Shareholder Return (“TSR”) and Research and Development (“R&D”) targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.
In addition, on 9 September 2026, nominal cost restricted share units (“RSUs”) over 50,566 ordinary shares in the Company (representing approximately 0.07 percent of the Company’s issued share capital) were granted to the two Executive Directors listed below. The RSUs were granted under the LTIP and will vest after the end of a three-year vesting period but are not subject to performance conditions being met. Further details on the RSUs can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.
|
Name |
Position |
Number of RSUs |
|
David Hallas |
Chief Executive Officer |
29,056 |
|
Chris Wilks |
Chief Financial Officer |
21,510 |
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group’s proprietary lead product, Aivlosin®is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group’s website or LinkedIn page for further information.
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
|
1. |
Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
|
a. |
Name |
David Hallas
| ||||||||||||
|
2. |
Reason for the notification | |||||||||||||
|
a. |
Position/status |
Chief Executive Officer
| ||||||||||||
|
b. |
Initial notification /Amendment
|
Initial notification | ||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
|
a. |
Name |
Eco Animal Health Group Plc | ||||||||||||
|
b. |
LEI |
2138009XN9DJ3YP7OB55 | ||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
| ||||||||||||
|
b. |
Nature of the transaction |
| ||||||||||||
|
c. |
Price(s) and volume(s) |
| ||||||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
| ||||||||||||
|
e. |
Date of the transaction |
9 September 2026 | ||||||||||||
|
f. |
Place of the transaction |
Off Market
| ||||||||||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
|
a. |
Name |
Chris Wilks
| ||||||||||||
|
2. |
Reason for the notification | |||||||||||||
|
a. |
Position/status |
Chief Financial Officer
| ||||||||||||
|
b. |
Initial notification /Amendment
|
Initial notification | ||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
|
a. |
Name |
Eco Animal Health Group Plc | ||||||||||||
|
b. |
LEI |
2138009XN9DJ3YP7OB55 | ||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
| ||||||||||||
|
b. |
Nature of the transaction |
| ||||||||||||
|
c. |
Price(s) and volume(s) |
| ||||||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
| ||||||||||||
|
e. |
Date of the transaction |
9 September 2026 | ||||||||||||
|
f. |
Place of the transaction |
Off Market
| ||||||||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.